Drugs / engineered autologous T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01140373 | Jun 2010 → Jun 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | engineered autologous T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01140373 ↗ |
| Modality | Cell therapy | “The immune cells (T cells) used in this study will be the patients own immune cells.” NCT01140373 ↗ |